Sana Biotechnology raises over $700M (SEC filings suggest $866.8M total) to advance gene and cell therapies

Sana Biotechnology announced it has raised more than $700 million in venture funding to develop gene- and cell-therapy approaches, marking one of the largest life-sciences venture rounds and among Seattles biggest. SEC filings indicate total capital and non-cash assets may total about $866.8 million, though the company declined to disclose valuation.

SSteve Harr SSana Biotechnology